TuHURA Biosciences, Inc./NV (HURA): Nasdaq/NYSE listing notice — Nasdaq extends Kintara's deadline to March 18, 2024 for stockholders' equity compliance

TuHURA Biosciences, Inc./NV

Original non-compliance notice received September 20, 2023 for $2.5M minimum stockholders' equity requirement.
Extension granted December 4, 2023, conditioned on achieving milestones in compliance plan submitted November 6, 2023.
If compliance not evidenced by March 18, 2024, Nasdaq may delist; company can appeal to hearings panel.
No immediate effect on listing; KTRA shares continue trading on Nasdaq Capital Market.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

November 6, 2023, the Company submitted to the Staff a plan to regain compliance with the Stockholders’ Equity Requirement. On December 4, 2023, the Staff provided notice (the “Notice”) to the Company that it granted an extension of up to 180 days from September 20, 2023, or through March 18, 2024, to regain compliance with the Stockholders’ Equity Requirement, conditioned upon the Company’s achievement of certain milestones included in the plan of compliance previously submitted to the Staff. If the Company fails to evidence compliance upon filing its periodic report for the quarter ending Ma

View on SEC.gov

1 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-067953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.